XIENCE

DEVICE13 trials

Sponsors

Seung-Jung Park, Abbott Medical Devices, European Cardiovascular Research Center, Insel Gruppe AG, University Hospital Bern, ECRI bv

Conditions

Acute Coronary SyndromeAnemiaBleeding DisorderCoagulation DisorderCoronary Artery DiseaseCoronary Artery LesionCoronary Artery LesionsCoronary Artery Stenosis

Unknown Phase

Evaluation of Everolimus-Eluting Stents (The K-XIENCE Registry)

CompletedNCT01350869

Seung-Jung ParkCoronary Artery Disease

Start: 2008-06-30End: 2014-06-30Target: 3000Updated: 2015-11-11

ABSORB III Randomized Controlled Trial (RCT)

CompletedNCT01751906

Abbott Medical DevicesCoronary Artery Disease, Coronary Artery Stenosis, Coronary Disease +1

Start: 2012-12-31End: 2020-10-31Updated: 2023-10-11

Absorb IV Randomized Controlled Trial

CompletedNCT02173379

Abbott Medical DevicesCoronary Artery Disease, Coronary Artery Stenosis, Coronary Disease +1

Start: 2014-07-31End: 2022-04-06Updated: 2023-10-30

ABSORB Bioresorbable Scaffold vs. Xience Metallic Stent for Prevention of Restenosis in Patients at High Risk of Restenosis

European Cardiovascular Research CenterCoronary Artery Lesion

Start: 2015-09-28End: 2024-09-30Updated: 2018-08-14

A Comparison of an Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent for Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

CompletedNCT02579031

Insel Gruppe AG, University Hospital BernAcute Coronary Syndrome, Coronary Artery Disease

Start: 2016-04-30End: 2020-05-31Updated: 2020-09-02

Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent

CompletedNCT02870140

ECRI bvCoronary Stenosis

Start: 2016-10-21End: 2020-08-26Updated: 2020-12-17

A Trial of Firesorb in Patients With Coronary Artery Disease: FUTURE-II

Shanghai MicroPort Medical (Group) Co., Ltd.Coronary Artery Disease

Start: 2017-08-24End: 2024-10-31Target: 430Updated: 2023-10-25

Efficacy of Angiolite Stent vs a Second-generation Drug-eluting Stent Xience for Percutaneous Coronary Intervention

CompletedNCT03049657

Cardiva2 S.L.Coronary Artery Disease, Drug-eluting Stent

Start: 2016-02-02End: 2019-01-28Updated: 2019-04-12

XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.

CompletedNCT03218787

Abbott Medical DevicesCoronary Artery Lesions

Start: 2017-07-19End: 2020-09-04Updated: 2021-11-05

XIENCE 28 Global Study

CompletedNCT03355742

Abbott Medical DevicesAnemia, Bleeding Disorder, Coagulation Disorder +6

Start: 2018-02-09End: 2020-04-30Updated: 2021-03-04

A Randomized Comparison of Long-Term Healing Between Biodegradable- Versus Durable-Polymer Everolimus Eluting Stents in STEMI

CompletedNCT03440801

Tokorozawa Heart CenterSTEMI - ST Elevation Myocardial Infarction

Start: 2017-07-03End: 2024-09-01Updated: 2025-09-08

XIENCE 28 USA Study

CompletedNCT03815175

Abbott Medical DevicesAnemia, Bleeding Disorder, Coagulation Disorder +6

Start: 2019-02-25End: 2021-02-04Updated: 2022-05-03

A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug-coated Stents and the Xience Drug-eluting Stent System in Patients With Acute Coronary Syndrome and High Bleeding Risk Using Optical Coherence Tomography

Not yet recruitingNCT07230847

China National Center for Cardiovascular DiseasesAcute Coronary Syndrome, Coronary Heart Disease

Start: 2025-12-01End: 2027-03-31Target: 60Updated: 2025-11-17

Related Papers

Low-Density Lipoprotein Cholesterol Levels and Neoatherosclerosis After STEMI: A Secondary Analysis of the CONNECT Randomized Clinical Trial.

2025-12-17

Long-term effect of biodegradable vs. durable polymer everolimus-eluting stents on neoatherosclerosis in ST-segment elevation myocardial infarction: the CONNECT trial.

2025-08-017 citations

Firesorb bioresorbable scaffold for de novo coronary artery disease: 1-year clinical outcomes.

2025-07-092 citations

Early and Late Outcomes With the Absorb Bioresorbable Vascular Scaffold: Final Report From the ABSORB Clinical Trial Program.

2025-01-018 citations

5-Year Outcomes After Bioresorbable Coronary Scaffolds Implanted With Improved Technique

Journal of the American College of Cardiology2023-05-1747 citations

Ultrathin-strut vs thin-strut drug-eluting stents for multi and single-stent lesions: A lesion-level subgroup analysis of 2 randomized trials

American Heart Journal2023-05-153 citations

Complex primary percutaneous coronary intervention with ultrathin‐strut biodegradable versus thin‐strut durable polymer drug‐eluting stents in patients with ST‐segment elevation myocardial infarction: A subgroup analysis from the BIOSTEMI randomized trial

Catheterization and Cardiovascular Interventions2023-02-192 citations

Sirolimus-eluting stents with ultrathin struts versus everolimus-eluting stents for patients undergoing percutaneous coronary intervention: final three-year results of the TALENT trial.

PubMed2022-08-1913 citations

Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI

Journal of the American College of Cardiology2021-11-0172 citations

Comparison of Clinically Adjudicated Versus Flow-Based Adjudication of Revascularization Events in Randomized Controlled Trials

Circulation Cardiovascular Quality and Outcomes2021-10-208 citations

Thinner Strut Sirolimus-Eluting BRS Versus EES in Patients With Coronary Artery Disease: FUTURE-II Trial.

2021-05-1813 citations

Intravascular ultrasound predictors of long-term outcomes following ABSORB bioresorbable scaffold implantation: A pooled analysis of the ABSORB III and ABSORB Japan trials.

2021-04-214 citations

Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial.

2021-04-203 citations

Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI

JACC: Cardiovascular Interventions2021-03-0155 citations

Biodegradable polymer sirolimus-eluting stents vs durable polymer everolimus-eluting stents in patients undergoing percutaneous coronary intervention: A meta-analysis of individual patient data from 5 randomized trials.

2021-02-1716 citations

A prospective multicentre randomized all-comers trial to assess the safety and effectiveness of the ultra-thin-strut sirolimus-eluting coronary stent Supraflex: 2-year results of the TALENT trial

European Heart Journal2020-11-012 citations

Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up: A Systematic Meta-analysis and Individual Patient Data Pooled Study.

2019-12-0168 citations

Clinical Outcomes Before and After Complete Everolimus-Eluting Bioresorbable Scaffold Resorption

Circulation2019-09-2587 citations

Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.

2019-09-02118 citations

Absorb Bioresorbable Scaffold Versus Xience Metallic Stent for Prevention of Restenosis Following Percutaneous Coronary Intervention in Patients at High Risk of Restenosis: Rationale and Design of the COMPARE ABSORB Trial.

2019-04-167 citations

12 more papers not shown